© 2022 MJH Life Sciences and Dermatology Times and Multimedia Medical, LLC. All rights reserved.
© 2022 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
January 18, 2022
The FDA approved the topical JAK1/JAK2 inhibitor ruxolitinib for the treatment of mild to moderate atopic dermatitis in September 2021.
Expert dermatologists provide an overview of vitiligo while reviewing presentation, diagnosis, and the goals of therapy related to current and future therapies.
The FDA has approved abrocitinib for adult patients with moderate to severe AD.
January 17, 2022
Targeting skin care regimens to the individual patient is most likely to yield compliance to a recommended routine.
Resident billing can have huge financial implications on academic institutions. A poster from the Icahn School of Medicine at Mount Sinai aimed to assess new medical coding lectures and a modified note template at Winter Clinical Dermatology Conference.
Clinicians provide insight into the risk of high systemic absorption levels with JAK inhibitor treatments.
AbbVie announces the approval after 3 studies show the efficacy and safety of upadacitinib using mono- and combination therapy.